CA-GLOBALLOGIC
Hitachi, Ltd. (TSE: 6501, “Hitachi”) and GlobalLogic*1 , a Hitachi Group Company, today announced the launch of a collaborative hub to promote digital transformation (DX) services in the Japanese market. Based in the Lumada Innovation Hub Tokyo*2 , a co-creation base for Hitachi, this collaboration hub combines capabilities of GlobalLogic and Lumada. Delivering on the joint integration strategy, this partnership aims to jump-start GlobalLogic’s entry into Japan, and will accelerate business development for design-led Digital Engineering services of GlobalLogic, establishing a system to support customers in Japan starting from fiscal 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210927005848/en/
"The market demand for DX continues to grow at a fast pace, as global brands increasingly leverage digital technologies to create new revenue streams and better engage customers,” said Nitesh Banga, Chief Operating Officer, GlobalLogic. “GlobalLogic and Hitachi are well positioned to address this need, and the launch of the collaboration Hub will be a great first step in bringing expanded DX capability to the Japan market."
Recently acquired by Hitachi in July 2021 and operating as a Hitachi Group Company, GlobalLogic is a leader in Digital Engineering services, with capabilities that span Strategy, Experience Design, and Chip-to-Cloud software engineering. GlobalLogic not only provides upstream services such as product ideation, but also implements that vision into actual products, platforms, and experiences.
Hitachi has the expertise and experience in DX that has been cultivated in the Lumada business, including design thinking and data science, and is working with customers and partners to create new value by combining wisdom and ideas.
As the first project to leverage the strengths of both companies, Hitachi and GlobalLogic have begun work to accelerate the transformation of Hitachi's Storage business into a cloud-based "as-a-Service" business model. This initiative will enable Hitachi and GlobalLogic to create and customize joint service offerings for the Japanese market.
About the Collaboration Between Hitachi and GlobalLogic
Lumada Innovation Hub Tokyo and GlobalLogic's design studios and engineering centers around the globe are connected online, and workshops are being conducted for collaborative projects, leveraging GlobalLogic's extensive DX implementation experience, experience design, and capabilities in Chip-to-Cloud software engineering. Hitachi and GlobalLogic will implement projects that accelerate DX for customers in Japan.
Design thinkers*3 from Lumada Innovation Hub Tokyo, with expertise in the industries and businesses of the Japanese market, will work with Hitachi business stakeholders and GlobalLogic's designers and solution architects to identify transformational goals. GlobalLogic's rapid problem-solving approach will be applied to develop DX strategies and quickly create business model prototypes.
The first workshop was held for Hitachi's storage business, where Hitachi and GlobalLogic worked on architectures to enhance cloud readiness. By leveraging GlobalLogic's digital engineering services, Hitachi will strengthen and accelerate its "as-a-Service" model for its storage business. Hitachi and GlobalLogic will apply the outcomes of this workshop to Hitachi's other product businesses to accelerate DX for its customers.
Future Opportunities
Based on the new, co-created business process established through this project, Hitachi will test its applicability against a variety of digital transformation projects and plans to launch the service to Japanese customers in fiscal 2022.
In the future, GlobalLogic's more than 22,000 design and software engineering professionals around the world and Hitachi's 35,000 digital professionals will work together through the Lumada Innovation Hub Tokyo to promote Social Innovation Businesses that leverage digital technology to solve problems faced by customers and society globally, including the Japanese market.
Collaboration Introduction at Hitachi Social Innovation Forum 2021 JAPAN
You can learn more about this collaboration at the “Hitachi Social Innovation Forum 2021 JAPAN” from October 11th (Monday) to 15th (Friday), 2021. The project will be showcased in the following sessions:
- October 11, 9:00-9:25 a.m. Keynote Speech: Toshiaki Higashihara "Future Achieved by DX of Social Infrastructure – Sustainable Society and Creative Consumer”
- October 12, 9:30-10:00 a.m. Highlight Session "Towards Becoming a Global DX Partner – Hitachi’s Acceleration of Global Lumada Business”
- October 12, 1:30-1:50 p.m. Seminar "How to Combine Knowledge and Ideas by Lumada”
Hitachi Social Innovation Forum 2021 JAPAN Official Site: https://www.service.event.hitachi/en/
About GlobalLogic
GlobalLogic (www.globallogic.com ) is a leader in digital product engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise -- we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the communications, financial services, automotive, healthcare and life sciences, technology, media and entertainment, manufacturing, and semiconductor industries. GlobalLogic is a Hitachi Group Company.
About Lumada Innovation Hub Tokyo
Lumada Innovation Hub Tokyo is a place where knowledge and ideas are crossed to stimulate innovation. It offers workshops and idea generation with digital human resources such as Design Thinkers and Data Scientists who are familiar with the Japanese market, as well as agile development services that utilize the Digital Transformation experience of the Lumada business.
https://www.hitachi.com/products/it/lumada/global/en/innovation_hub/index.html
About Hitachi, Ltd.
Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, is contributed to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business. Hitachi is focused on strengthening its contribution to the Environment, the Resilience of business and social infrastructure as well as comprehensive programs to enhance Security & Safety. Hitachi resolves the issues faced by customers and society across six domains: IT, Energy, Mobility, Industry, Smart Life and Automotive Systems through its proprietary Lumada solutions. The company’s consolidated revenues for fiscal year 2020 (ended March 31, 2021) totaled 8,729.1 billion yen ($78.6 billion), with 871 consolidated subsidiaries and approximately 350,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com .
*1 - July 14, 2021 News Release "Hitachi Completes Acquisition of GlobalLogic” https://www.hitachi.com/New/cnews/month/2021/07/f_210714.pdf
*2 - March 22, 2021 News Release " Hitachi Establishes Lumada Innovation Hub Tokyo to Accelerate the Lumada Movement Through New Collaborative Creation With a View to the Post-COVID-19 World” https://www.hitachi.com/New/cnews/month/2021/03/210322a.html
*3 - Design Thinker: Digital human resources who can discover essential corporate issues and propose DX by utilizing design thinking.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005848/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom